Retrospective analysis of Hormonal Maintenance Therapy for Patients With LGS Ovarian Cancer

Trial ID # Retrospective Study: Hormonal Maintenance in LGSC
Phase II
Drug Class Hormonal Therapy: Aromatase
Drug Name Anastrozole, Letrozole
Alternate Drug Names Arimidex, Femara
Drugs in Trial Anastrozole, Letrozole, Tamoxifen
Eligible Participant

Stage II-IV low grade serous ovarian cancer after surgery and first-line therapy

Patients Enrolled

203

Therapy Setting

Maintenance

Study Design

Open-Label, Non-randomized

Endpoints

PFS, OS, evaluated per RECIST or CA125

Efficacy

Hormonal maintenance therapy (HMT)(n=70) vs routine observation (OBS)(n=133):

PFS: 64.9 vs 26.4 months (p<0.001)
OS: 115.7 vs 102.7 months (n.s.)

Conclusion

Significantly longer PFS with hormonal maintenance therapy (HMT) vs. observation in Low Grade Serous OC patients

Reference

Gershenson DM et al. Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum. J Clin Oncol (2017) 35: 1103-1111
https://www.ncbi.nlm.nih.gov/pubmed/28221866